Takeda Pharmaceutical Company Limited TKPYY today announced that the European Medicines Agency (EMA) has
accepted the Marketing Authorization Application (MAA) for ixazomib, an
investigational oral proteasome inhibitor for the treatment of patients
with relapsed and/or refractory multiple myeloma. On July 23, ixazomib
was granted accelerated assessment by the Committee for Medicinal
Products for Human Use (CHMP) of the EMA, a designation reserved for
those medicines deemed to be of major public health interest and, in
particular, therapeutic innovation.
"The ixazomib applications in Europe and the United States are the first
of several that we anticipate submitting by the end of this fiscal
year," said Melody Brown, Vice President of Regulatory Affairs,
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in